Neurodegeneration with brain iron accumulation

Handbook of Clinical Neurology

Volumn 100, Issue , 2011, Pages 161-172

  Mcneill, Alisdair ^a   Chinnery, Patrick F ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CERULOPLASMIN; IRON;

BOOK; BRAIN; DEGENERATIVE DISEASE; GENETICS; HUMAN; IRON METABOLISM DISORDER; METABOLISM; METHODOLOGY; NEUROAXONAL DYSTROPHY; NEUROFERRITINOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION; PATHOLOGY;

BRAIN; CERULOPLASMIN; HUMANS; IRON; IRON METABOLISM DISORDERS; MAGNETIC RESONANCE IMAGING; NEUROAXONAL DYSTROPHIES; NEURODEGENERATIVE DISEASES; PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION;

EID: 79954478445     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52014-2.00009-4     Document Type: Book

References (55)

1. Baumeister F.A., Auer D.P., Hörtnagel K., et al. The eye-of-the-tiger sign is not a reliable disease marker for Hallervorden-Spatz syndrome. Neuropediatrics 2005, 36:221-222.
2. Castelnau P., Cif L., Valente E.M., et al. Pallidal stimulation improves pantothenate kinase associated neurodegeneration. Ann Neurol 2005, 57:738-741.
3. Chinnery P.F., Crompton D.E., Birchall D., et al. The clinical features and natural history of neuroferritinopathy caused by the FTL1 460insa mutation. Brain 2007, 130:110-119.
4. Curtis A.R., Fey C., Morris C.M., et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult onset basal ganglia disease. Nat Genet 2001, 28:350-354.
5. Daimon M., Susa S., Ohizumi T., et al. A novel mutation of the ceruloplasmin gene in a patient with heteroallelic ceruloplasmin gene mutation (hypocpgm). Tohuku J Exp Med 2000, 191:119-125.
6. Devos D., Tchofo J., Vuillaume, et al. Clinical features and natural history of neuroferritinopathy caused by the 458dupa FTL mutation. Brain 2008, 132:e109.
7. Forni G.L., Balocco M., Cremonesi L., et al. Regression of symptoms after selective iron chelation in a case of neurodegeneration with brain iron accumulation. Mov Disord 2008, 23:904-907.
8. Gerlach M., Double K.L., Youdim M.B., et al. Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl 2006, 70:133-142.
9. Ge Y., Jensen J.H., Lu H., et al. Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. AJNR Am J Neuroradiol 2007, 28:1639-1644.
10. Gonzalez-Cuyar L.F., Perry G., Miyajima H., et al. Redox active iron accumulation in aceruloplasminemia. Neuropathol 2008, 28:466-471.
11. Gregory A., Hayflick S.J. Neurodegeneration with brain iron accumulation. Folia Neuropathol 2005, 43:286-296.
12. Gregory A., Westaway S.K., Holm I.E., et al. Neurodegeneration associated with genetic defects in phospholipase A2. Neurology 2008, 71:1-8.
13. Haemers I., Kono S., Goldman S., et al. Clinical, molecular and PET study of a case of aceruloplasminemia presenting with focal cranial dyskinesia. J Neurol Neurosurg Psych 2004, 75:334-337.
14. Hartig M.B., Hortnagel K., Garavaglia B., et al. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol 2006, 59:248-256.
15. Hautot D., Pankhurst Q.A., Morris C.M., et al. Preliminary observation of elevated levels of nanocrystalline iron oxide in the basal ganglia of neuroferritinopathy patients. Biochem Biophys Acta 2007, 1772:21-25.
16. Hayflick S.J., Westaway S.K., Levinson B., et al. Genetic, clinical, and radiographic delineation of Hallervordern-Spatz syndrome. N Engl J Med 2003, 348:33-40.
17. House M.J., St Pierre T.G., Kowdley K.V., et al. Correlation of proton transverse relaxation rates (R2) with iron concentrations in postmortem brain tissue from Alzheimer's disease patients. Magn Reson Med 2007, 57:172-180.
18. Kaneko K., Yoshida K., Arima K., et al. Astrocytic deformity and globular structures are characteristic of the brains of patients with aceruloplasminemia. J Neuropathol Exp Neurol 2002, 61:1069-1077.
19. Kohno S., Miyajima H., Takahashi Y. Aceruloplasminemia with a novel mutation associated with parkinsonism. Neurogenetics 1999, 2:237-238.
20. Kohno S., Miyajima H., Takahashi Y., et al. Defective electron transfer in complexes I and IV in patients with aceruloplasminemia. J Neurol Sci 2000, 182:57-60.
21. Kono S., Miyajima H. Molecular and pathological basis of aceruloplasminemia. Biol Res 2006, 39:15-23.
22. Kotzbauer P.T., Truax A.C., Trojanowski J.Q., et al. Altered neuronal mitochondrial coenzyme A synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2. J Neurosci 2005, 19:689-698.
23. Kuhn J., Bewermeyer H., Miyajima H., et al. Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate. Brain Dev 2007, 29:450-453.
24. Kumar N., Boes C.J., Babovic-Vuksanovic D., et al. The " eye-of-the-tiger" sign is not pathognomonic of the PANK2 mutation. Arch Neurol 2006, 63:292-293.
25. Kuo Y.M., Duncan J.L., Westaway S.K. Deficiency of pantothenate kinase 2 (Pank2) in mice leads to retinal degeneration and azoospermia. Human Mol Genet 2005, 14:49-57.
26. Kuo Y.M., Hayflick S.J., Gitshier J. Deprivation of pantothenic acid elicits a movement disorder and azoospermia in a mouse model of pantothenate kinase-associated neurodegeneration. J Inherit Metab Dis 2007, 30:310-317.
27. Kurian M.A., Morgan N.V., MacPherson L., et al. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 2008, 70:1623-1629.
28. Maciel P., Cruz V.T., Constante M., et al. Neuroferritinopathy: missense mutation in FTL causing early-onset bilateral pallidal involvement. Neurology 2005, 65:603-605.
29. Malik I., Turk J., Mancuso D.J., et al. Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations. Am J Pathol 2008, 172:406-416.
30. Mancuso M., Davidzon G., Kurlan R.M., et al. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J Neuropathol Exp Neurol 2005, 64:280-294.
31. McNeill A., Birchall D., Hayflick S.J., et al. T2* and FSE MRI distinguishes 4 subtypes of neurodegeneration with brain iron accumulation. Neurology 2008, 70:1614-1619.
32. McNeill A., Pandolfo M., Shang H., et al. The neurological presentation of ceruloplasmin gene mutations. Eur Neurol 2008, 60:200-206.
33. Metafratzi Z., Argyropoulou M.I., Kiortsis D.N., et al. T(2) relaxation rate of basal ganglia and cortex in patients with beta-thalassaemia major. Br J Radiol 2001, 74:407-410.
34. Miszkiel K.A., Paley M.N., Wilkinson I.D., et al. The measurement of R2, R2* and R2' in HIV-infected patients using the prime sequence as a measure of brain iron deposition. Magn Reson Imaging 1997, 15:1113-1119.
35. Miyajima H., Ikeda S., Yamamoto K., et al. Hereditary ceruloplasmin deficiency: a clinicopathological study of a Japanese family. Ann Neurol 1995, 36:646-656.
36. Miyajima H., Kono S., Takahashi Y., et al. Cerebellar ataxia associated with heteroallelic ceruloplasmin gene mutation. Neurology 2001, 57:2205-2210.
37. Miyajima H., Adachi J., Kohno S., et al. Increased oxysterols associated with iron accumulation in the brains and visceral organs of aceruloplasminemia patients. QJM 2001, 94:417-422.
38. Miyajima H., Takahashi Y., Kono S. Aceruloplasminemia, an inherited disorder of iron metabolism. Biometals 2003, 16:205-213.
39. Miyajima J., Takahashi Y., Kamata T., et al. Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 1997, 41:404-407.
40. Molinuevo J.L., Marti M.J., Blesa R., et al. Pure akinesia: an unusual phenotype of Hallervorden-Spatz syndrome. Mov Disord 2003, 18:1351-1353.
41. Morgan N.V., Westawat S.K., Morton J.E., et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 2006, 38:752-754.
42. Ohta E., Nagasaka T., Shindo K., et al. Neuroferritinopathy in a Japanese family with a duplication in the ferritin light chain gene. Neurology 2008, 70:1493-1494.
43. Oide T., Yoshida K., Kaneko K., et al. Iron overload and antioxidative role of perivascular astrocytes in aceruloplasminemia. Neuropath Appl Neurobiol 2006, 32:170-176.
44. Paisan-Ruiz C., Bhatia K.P., Hernandez D., et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 2008, 65:19-23.
45. Pellecchia M.T., Valente E.M., Cif L., et al. The diverse phenotype and genotype of pantothenate-kinase associated neurodegeneration. Neurology 2005, 64:1810-1812.
46. Powers J.M. P53-mediated apoptosis, neuroglobulin overexpression, and globin deposits in a patient with hereditary ferritinopathy. J Neuropathol Exp Neurol 2006, 65:716-721.
47. Skidmore F.M., Drago V., Foster P., et al. Aceruloplasminemia with progressive atrophy without brain iron overload: treatment with oral chelation. J Neurol Neurosurg Psych 2007, 79:467-470.
48. Streker K., Hesse S., Wegner F., et al. Eye of the tiger sign in Multiple Systems Atrophy. Eur J Neurol 2007, 14:e1-e2.
49. Tofaris G.K., Revesz T., Jacques T.S., et al. Adult-onset neurodegeneration with brain iron accumulation and cortical alpha-synuclein and tau pathology: a distinct clinicopathological entity. Arch Neurol 2007, 64:280-282.
50. Vasconcelos O.M., Harter D.H., Duffy C., et al. Adult Hallervorden-Spatz simulating amyotrophic lateral sclerosis. Muscle Nerve 2003, 28:118-122.
51. Vidal R., Ghetti B., Takao M., et al. Intracellular ferritin accumulation in neuronal and extra-neuronal tissues characterises a neurodegenerative disorder associated with a mutation in the ferritin light polypeptide gene. J Neuropath Exp Neurol 2004, 63:363-380.
52. Vidal R., Miravalle L., Gao X., et al. Expression of a mutant form of the ferritin light chain gene induces neurodegeneration and iron overload in transgenic mice. J Neurosci 2008, 28:60-67.
53. Yang Y., Wu Z., Kuo Y.M., et al. Dietary rescue of fumble - a Drosophila model for pantothenate-kinase-associated neurodegeneration. J Inherit Metab Dis 2005, 28:1055-1064.
54. Yonekawa M., Okabe T., Asamoto Y., et al. A case of hereditary ceruloplasmin deficiency with iron deposition in the brain associated with chorea, dementia, diabetes mellitus and retinal pigmentation: administration of fresh frozen plasma. Eur Neurol 1999, 42:157-162.
55. Zhou B., Westaway S.K., Levinson B., et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001, 28:345-349.